Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of oral hydroxyurea solution in pediatric sickle cell anemia
2017-004568-37Phase 2Unknown
- Sponsor
- Nova Laboratories
- Start
- Sep 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxyurea in sickle cell anemia (SCA), sponsored by Nova Laboratories. Primary endpoints: Pharmacokinetics of oral hydroxyurea solution and Safety of oral hydroxyurea solution. Status: unknown.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on 2017-004568-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004568-37.